Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Search results (6)

« Back to Publications

Mutant TDP-43 drives impairments in axonal transport and glycolysis in a mouse stem-cell-derived motor neuron model of amyotrophic lateral sclerosis (ALS).

Carroll E. et al, (2026), Cell Death Dis, 17

Recent developments in gene therapy for Parkinson's disease.

Szunyogh S. et al, (2025), Mol Ther, 33, 2052 - 2064

Drug repurposing in amyotrophic lateral sclerosis (ALS).

Carroll E. et al, (2025), Expert Opin Drug Discov, 20, 447 - 464

Dynactin-1 mediates rescue of impaired axonal transport due to reduced mitochondrial bioenergetics in amyotrophic lateral sclerosis motor neurons.

Dafinca R. et al, (2024), Brain Commun, 6

C9orf72-ALS human iPSC microglia are pro-inflammatory and toxic to co-cultured motor neurons via MMP9.

Vahsen BF. et al, (2023), Nat Commun, 14

Targeting phosphoglycerate kinase 1 with terazosin improves motor neuron phenotypes in multiple models of amyotrophic lateral sclerosis.

Chaytow H. et al, (2022), EBioMedicine, 83